Rita Leporati, Daniela Miliziano, Teresa Beninato, Laura Mazzeo, Sara Manglaviti, Marta Brambilla, Mario Occhipinti, Arsela Prelaj, Claudia Proto, Giuseppe Lo Russo
INTRODUCTION: Several anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have been developed for the treatment of echinoderm microtubule-associated protein-like 4 (EML4)-ALK-rearranged non-small cell lung cancer (NSCLC), with the newer generation agents brigatinib, alectinib and lorlatinib showing prolonged responses. With the increasing number of target therapies available, the optimal sequence is yet to be defined, as resistance profiles may evolve over time and in response to sequential ALK inhibitors...
April 16, 2024: Tumori
Francesco Tucci, Arvydas Laurinavicius, Jakob Nikolas Kather, Catarina Eloy
Artificial intelligence (AI) applications in oncology are at the forefront of transforming healthcare during the Fourth Industrial Revolution, driven by the digital data explosion. This review provides an accessible introduction to the field of AI, presenting a concise yet structured overview of the foundations of AI, including expert systems, classical machine learning, and deep learning, along with their contextual application in clinical research and healthcare. We delve into the current applications of AI in oncology, with a particular focus on diagnostic imaging and pathology...
April 12, 2024: Tumori
Andrea Ferrari, Teresa Perillo, Giuseppe Maria Milano, Matteo Silva, Chiara Rutigliano, Andrea Salvo, Virginia Livellara, Massimo Conte, Luca Coccoli, Elena Amore, Marta Pierobon, Francesco Vietina, Elena Pagani Bagliacca, Marco Spinelli, Maria Speranza Massei, Valentina Massetti, Elena Legnani, Ilaria Puglisi, Giulia Zucchetti, Paola Quarello
This article describes the oncology programs developed in Italy for adolescents and young adults with cancer, with a specific focus on the local projects created in pediatric oncology centers. A common feature of such projects is the emphasis on creative and artistic activities and laboratories (involving music, photography, novel writing, fashion design, and so on) designed to give young patients innovative means of expression.This article highlights the amazing powers of adolescents involved in these projects: the power to produce beautiful things in a place that is not normally associated with the idea of beauty; the power to make their doctors smile and grasp the profound sense of life; the power to make hospitals become places for producing culture...
April 9, 2024: Tumori
Mutahar A Tunio, Nicki Davies, Elliot Caparros, Janis Davies, Stuart Foyle
AIM: To review a five-year clinical practice of radical chemoradiotherapy (CRT) for anal cancers at a cancer centre in Wales. METHODS: A retrospective audit examined the quality of radical CRT for anal cancers treated between November 2016 and November 2021 by investigating seven critical indicators set by Radiation Therapy Oncology Group and ACT II trials, (1) 95% completion of computed tomography simulation within 14 days of consent, (2) 100% CRT delivery within 28 days of computed tomography simulation, (3) 100% CRT delivery within 28 days of consent, (4) overall treatment time of RT 38 days with > 2 days breaks <5%, (5) 75% completion of concurrent chemotherapy, (6) <2% CRT related colostomies, and (7) <2% the 30-days mortality rate...
March 29, 2024: Tumori
Erkan Topkan, Efsun Somay, Ugur Selek
No abstract text is available yet for this article.
March 12, 2024: Tumori
Anna Amela Valsecchi, Vittorio Fusco, Massimo Di Maio, Daniele Santini, Marcello Tucci, Ugo De Giorgi, Rossana Dionisio, Francesca Vignani, Saverio Cinieri
PURPOSE: Cancer treatment-induced bone loss is a side effect of hormonal therapy that can severely affect patients' quality of life. The aim of this survey was to obtain an updated picture of management of bone health in patients with breast cancer undergoing adjuvant hormonal therapy and in patients with hormone sensitive prostate cancer according to Italian oncologists. METHODS: Our survey was made up of 21 multiple-choice questions: the first part dealt with the respondents' characteristics, while the second with management of bone health in the described setting...
March 10, 2024: Tumori
Luigi Cerbone, Sara Delfanti, Stefania Crivellari, Antonina Maria De Angelis, Laura Mazzeo, Claudia Proto, Mario Occhipinti, Giuseppe Lo Russo, Chiara Dellepiane, Federica Biello, Irene Alabiso, Francesco Verderame, Roberta Gauna, Irene De Simone, Federica Cuppone, Sandra Petraglia, Giulia Pasello, Giovanni Luca Ceresoli, Marina Chiara Garassino, Valter Torri, Federica Grosso
BACKGROUND: Pleural mesothelioma is a rare cancer with a dismal prognosis and few therapeutic options, especially in the pretreated setting. Immunotherapy with checkpoint inhibitors as single agents yielded interesting results in refractory pleural mesothelioma, achieving a response rate between 10-20%, median progression-free survival of 2-5 months and median overall survival of 7-13 months. PATIENTS AND METHODS: A retrospective, multi-institutional study of pleural mesothelioma patients treated with nivolumab in second and further line was performed...
February 19, 2024: Tumori
Ida Taglialatela, Alice Indini, Giulia Santanelli, Giorgia Di Liberti, Lorenza Di Guardo, Filippo De Braud, Michele Del Vecchio
Cutaneous melanoma represents the fifth tumor in terms of incidence in young adults, with a major involvement of males than females. Despite the significant changes in available effective treatments for cutaneous melanoma, there is still a proportion of patients that do not benefit long-term disease control with immune checkpoint inhibitors and/or BRAF/MEK inhibitors, and eventually develop progressive disease. In addition to the emerging biomarkers under investigation to understand resistance to treatments, recent studies resumed the role of sex hormones (estrogens, progesterone and androgens) in melanoma patients...
February 19, 2024: Tumori
Emanuele Crocetti, Alessandra Ravaioli, Fabio Falcini, Rosa Vattiato, Silvia Mancini, Flavia Baldacchini, Federica Zamagni, Benedetta Vitali, Chiara Balducci, Lauro Bucchi, Orietta Giuliani
INTRODUCTION: This cross-sectional study was aimed at estimating the number of Italian incident cancer patients in 2020 eligible for, and respondent to, immune checkpoint inhibitors (ICI). METHODS: The study is based on publicly available data: the ICI approved until August 2022 by the Italian Medicines Agency (AIFA) with their specific indications and overall observed responses, rther details can be found in the Online Supplementary Materi cancer incidence estimates at 2020 and observed cancer deaths, and published papers with estimates on the frequency of different cancer stage/histology/markers etc...
February 19, 2024: Tumori
Desirèe Speranza, Elena Sapuppo, Giuseppe Aprile, Alessandra Auriemma, Francesca Bergamo, Roberto Bianco, Roberto Bordonaro, Giovanni Brandi, Oronzo Brunetti, Carlo Carnaghi, Domenico Ciliberto, Saverio Cinieri, Salvatore Corallo, Ferdinando De Vita, Samantha Di Donato, Francesco Ferraù, Lorenzo Fornaro, Viola Barucca, Elisa Giommoni, Claudio Lotesoriere, Claudio Luchini, Cristina Masini, Monica Niger, Salvatore Pisconti, Ilario Giovanni Rapposelli, Lorenza Rimassa, Chiara Rognone, Maria Grazia Rodriquenz, Lidia Rita Corsini, Daniele Santin, Aldo Scarpa, Mario Scartozzi, Hector Soto Parra, Giuseppe Tonini, Giampaolo Tortora, Paolo Tralongo, Nicola Silvestris
INTRODUCTION: About 90% of cholangiocarcinomas are adenocarcinomas with glandular or tubular structures lined by epithelial cells, with no bile production and with a variable degree of differentiation, arising in the background of desmoplastic stroma. The remaining 10% is represented by rarer histological variants of which there is little knowledge regarding the biological behavior, molecular characterization, and sensitivity to the various possible therapies, including molecular-based treatments...
February 7, 2024: Tumori
Min Ma, Yazhi Zhu, Changkai Xiao, Ruidong Li, Xingyu Cao, Ran Kang, Xiaolan Wang, Ermao Li
Prostate cancer is the second most common malignancy among men in the world, posing a serious threat to men's health and lives. RB1 is the first human tumor suppressor gene to be described, and it is closely associated with the development, progression, and suppression of a variety of tumors. It was found that the loss of RB1 is an early event in prostate cancer development and is closely related to prostate cancer development, progression and treatment resistance. This paper reviews the current status of research on the relationship between RB1 and prostate cancer from three aspects: RB1 and prostate cell lineage plasticity; biological behavior; and therapeutic resistance...
February 5, 2024: Tumori
Giulia Corrao, Luca Bergamaschi, Vanessa Eleonora Pierini, Aurora Gaeta, Stefania Volpe, Matteo Pepa, Mattia Zaffaroni, Maria Giulia Vincini, Cristiana Iuliana Fodor, Gaia Piperno, Francesca Emiro, Annamaria Ferrari, Sara Gandini, Federica Cattani, Roberto Orecchia, Giulia Marvaso, Barbara Alicja Jereczek-Fossa
PURPOSE: Hippocampal sparing whole-brain radiotherapy (HS-WBRT) showed significantly lower long-term side effects compared to standard WBRT. Aim of this study is to describe a HS-WBRT real-world monoinstitutional experience within a retrospective cohort. METHODS: Patients who completed HS-WBRT course, with Karnofsky Performance Status ⩾ 60 and radiological diagnosis of brain metastases (BMs) were enrolled. Treatment was performed using helical Tomotherapy scheduled in 30 Gy in 10 or 12 fractions or 25 Gy in 10 fractions...
February 2024: Tumori
Clorinda Brignola, Sara Volorio, Giovanna De Vecchi, Daniela Zaffaroni, Valentina Dall'Olio, Frederique Mariette, Domenico Sardella, Fabio Capra, Stefano Signoroni, Emanuele Rausa, Marco Vitellaro, Valeria Pensotti, Maria Teresa Ricci
Lynch Syndrome is an autosomal dominant cancer predisposition syndrome caused by germline pathogenic variants or epimutation in one of the DNA mismatch repair genes. De novo pathogenic variants in mismatch repair genes have been described as a rare event in Lynch Syndrome (1-5%), although the prevalence of de novo pathogenic variants in Lynch Syndrome is probably underestimated. The de novo pathogenic variant was identified in a 26-year-old woman diagnosed with an adenocarcinoma of the caecum with mismatch repair protein deficiency at immunohistochemistry and a synchronous neuroendocrine tumor of the appendix with normal expression of mismatch repair proteins...
February 2024: Tumori
Jianjun Ye, Xinyang Liao, Yu Qiu, Qiang Wei, Yige Bao
OBJECTIVE: The expression and significance of human epidermal growth factor receptor 2 (Her2) in upper tract urothelial carcinoma (UTUC) remains controversial. Thus, we aimed to systemically review the Her2 expression in UTUC patients and its relationship with pathological characters and clinical outcomes with meta-analysis. MATERIALS AND METHODS: A systematically computerized search in PubMed, Scopus, Embase and Cochrane was conducted. From a total of 454 related articles, 35 articles were finally reviewed and 16 papers were chosen for further analysis...
February 2024: Tumori
Min Zhao, Lixing Wang, Xingyu Wang, Juan He, Kuai Yu, Dan Li
The microenvironment of diffuse large B-cell lymphoma (DLBCL) is composed of various components, including immune cells and immune checkpoints, some of which have been correlated with the prognosis of DLBCL, but their results remain controversial. Therefore, we conducted a systematic review and meta-analysis to investigate the association between the microenvironment and prognosis in DLBCL. We searched PubMed, Web of Science, and EMBASE for relevant articles between 2001 and 2022. Twenty-five studies involving 4495 patients with DLBCL were included in the analysis...
January 5, 2024: Tumori
Amelia Barcellini, Chiara Cassani, Ester Orlandi, Rossella E Nappi, Federica Broglia, Maria Paola Delmonte, Silvia Molinelli, Alessandro Vai, Viviana Vitolo, Alessandro Gronchi, Gioacchino D'Ambrosio, Lorenzo Cobianchi, Maria Rosaria Fiore
INTRODUCTION: Preserving the endocrine and reproductive function in young female cancer patients undergoing pelvic radiation is a significant challenge. While the photon beam radiation's adverse effects on the uterus and ovaries are well established, the impact of pelvic carbon ion radiotherapy on women's reproductive function is largely unexplored. Strategies such as oocyte cryopreservation and ovarian transposition are commonly recommended for safeguarding future fertility. METHODS: This study presents a pioneering case of successful pregnancy after carbon ion radiotherapy for locally advanced sacral chondrosarcoma...
January 5, 2024: Tumori
Antonio Silvani, Enrico Franceschi
No abstract text is available yet for this article.
January 2, 2024: Tumori
Paolo Pozzi, Roberto Boffi, Chiara Veronese, Sara Trussardo, Camilla Valsecchi, Federica Sabia, Ugo Pastorino, Giovanni Apolone, Elisa Cardani, Francesco Tarantini, Elena Munarini
INTRODUCTION: Cigarette smoke accounts for over 90,000 deaths each year in Italy. Tobacco dependence treatment guidelines suggest adopting an integrated pharmacological-behavioral model of intervention. Cytisine is a partial agonist of nicotinic receptors. Trials conducted to date have demonstrated its good efficacy in promoting smoking cessation. The cytisine scheme of treatment consists of 25 days of treatment. A 40-day regimen, with an escalating dose and an extended duration of the treatment, has been in use in many anti-smoking centers in Italy for several years, but to date there are no reports on the use of cytisine with this scheme...
December 27, 2023: Tumori
Ushna Zameer, Wajiha Shaikh
Cisplatin-based combos have become first-line treatment regimens in standard of care because of their high overall survival improvement. Despite being the first-line therapy, due to its side effects, roughly half of all patients suffering from Metastatic urothelial cancer are ineligible for it. To address this issue, scientists have been developing highly specific antibody-drug conjugates to address this issue. For locally advanced or metastatic bladder cancer, a combination of Padcev (enfortumab vedotin-ejfv) with pembrolizumab (Keytruda) has been authorized by the FDA as a first-line treatment and has shown promising outcomes in patients with metastatic urothelial carcinoma who are ineligible for cisplatin-based combinations...
December 23, 2023: Tumori
Simone Nardin, Tommaso Ruelle, Irene Giannubilo, Lucia Del Mastro
Breast cancer is the most common cancer in women, and luminal breast cancer is the predominant subtype, characterized by the presence of estrogen receptors and/or progesterone receptors in tumor cells. Adjuvant endocrine therapy is the pivotal approach in the management of luminal early breast cancer. Hence, new therapeutic approaches have been studied during the last few years, especially in patients with high risk of recurrence.Here we provide a summary of the most recent clinical trials evaluating adjuvant treatment in hormone-receptors-positive early breast cancer...
December 19, 2023: Tumori
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.